Elevated serum alpha subunit levels in patients with cancer; a consequence of gonadotrophin secretion and age. by Chapman, A. J. et al.
Br. J. Cancer (1987), 56, 493-494
© The Macmillan Press Ltd.,
SHORT COMMUNICATION
Elevated serum x subunit levels in patients with cancer; a consequence of
gonadotrophin secretion and age
A.J. Chapman', S.M. Shalet1, C.G. Beardwell', N. Thatcher2 & E.L. Robinson3
Departments of 'Endocrinology and 2Medical Oncology, Christie Hospital and Holt Radium Institute, Manchester M20 9BX and
3Regional Radioimmunoassay Laboratory, Department ofChemical Pathology, University Hospital ofSouth Manchester,
Manchester M20 8LR, UK.
Serum concentrations of glycoprotein hormone oa subunit are
raised in some patients with tumours (Franchimont et al.,
1972; Dosogne-Guerin et al., 1978) and ectopic synthesis and
secretion of a subunit has been demonstrated using various
in vitro methods (Weintraub et al., 1973; Walker 1978).
Serum a subunit may be of value, therefore as a marker in
patients with certain types of tumour. The serum concen-
tration depends partly upon secretion from the pituitary
which is linked to that of the intact glycoprotein hormones,
as well as on possible ectopic secretion. Concentrations are
increased in hypergonadotrophic states such as after the
menopause (Kourides et al., 1977) and at the time of the pre-
ovulatory LH surge (Rosemberg & Bulat, 1979) compared to
those seen in men and pre-menopausal women during most
of the menstrual cycle. Serum a subunit levels in patients
with tumours have usually been compared with the concen-
trations found in normal subjects of similar age and sex.
This method does not allow for possible variation in
gonadotrophin levels between patients and controls. We
have used multiple regression analysis (MR) to correlate
gonadotrophin and a subunit concentrations. Using this
method we have calculated the prevalence of increased
serum a subunit levels in patients with hypernephroma and
compared this with results obtained by reference to the 95%
confidence limits of serum oa subunit concentrations in
control groups. Differences in the results obtained by the
two methods indicate important problems when deciding
upon an appropriate normal range definition when ac subunit
concentration is being used as a serum tumour marker.
Blood samples were obtained from 132 healthy volunteers
and 38 patients with hypernephroma. Samples from the
patients were taken at diagnosis, before any treatment, and
at various intervals after nephrectomy. Serum was stored at
-20'C until required. Hypernephroma has been reported to
be associated with elevated serum a subunit levels (Dosogne-
Gu6rin et al., 1978). The treatment protocol included neither
hormonal nor cytotoxic therapy, either of which could
interfere with gonadal function independently of any effect
of malignancy upon gonadotrophin levels.
Serum a subunit, LH, FSH, TSH and urea were measured
in all samples. Serum a subunit was measured according to
previously published methods from this laboratory. The
upper limit of normal, defined as the 95% confidence limits
for oc subunit, was <2.3ngnl-1 in men and pre-menopausal
women and <9.5 ngml-1 in post-menopausal women. In the
a subunit assay, cross reaction of LH (NIBSC 68/40) was
12.5% (MacFarlane et al., 1979,1982).
LH and FSH were measured using double antibody radio-
immunoassays. The standards were NIBSC 68/40 for LH
and NIBSC 78/549 for FSH. Antisera WRB F 87.2 (for LH)
and WRB M 93.2 were kindly denoted by Professor W.R.
Table I a subunit levels defined by
limits
Normal
17
Normal Elevated
95% confidence
Elevated
6
Normal Elevated
a subunit
defined by MR 14 3 3 3
Pre-operative alpha subunit levels in 23 men with
hypernephroma as defined by both MR and 95%
confidence limits. The table illustrates the discrepancies
obtained between the two methods.
Butt. In the LH assay, cross reaction of a subunit was 0.5%.
The TSH assay was also a double antibody radioimmuno-
assay using standard NIBSC 68/38 and antiserum kindly
provided by the Tenovus Institute. Blood urea was measured
using the Chemispek Instrument (Rank-Hilger, Margate).
Multiple regression analysis (MR) of oa on LH, FSH and
age was determined by using the GLIM computer program
package.
Using MR, serum LH was the single most important
predictor of serum a subunit concentration, followed by age,
in the control group of 132 healthy men, pre-menopausal
women and post-menopausal women. The age range of this
group was 17-76 years, with a mean of 35.1 years. No other
combination of serum FSH or sex, when added to LH and
age, significantly improved the regression. The final model
obtained was:
a(ngml) =K2 +K2 LH (IU1) +K3 age (years),
where
K1 =0.3504+0.06
K2 =0.540+0.04
K3 =0.019+0.05
The predictive value of age could not be explained by an
increasing percentage of primary hypothyroidism or renal
failure, as determined by serum TSH and urea estimation.
Thirty eight patients with hypernephroma were studied, 23
men, age range 37-72 years, and 15 women, range 26-71
years. Of the women, 5 were pre-menopausal and 10 were
post-menopausal. The mean (±s.d.) of pre-treatment serum
ac subunit values in the men were 2.0+0.9ngml-1, range
<0.5-3.8ngml 1, and in the women 2.8-2.1 ngml-1, range
<0.5-7.6ngml-1
Six of 23 men had serum a subunit values >2.3ngml1,
whilst only one woman had a raised value (3.8 ngml 1 in a
pre-menopausal woman).
The mean pre-treatment serum LH values in the men were
15.72IU1 1, range 4-48, and 21.8 IUl-','range 5-50, in the
women.
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Mean serum LH, +1 s.d. in the 6 men with ca subunit
concentrations greater than 2.3 ngml -1 was 28 + 16.2 IU 1- I
compared with 11 +6.0 IU 1-1 in the remaining 17; their
mean ages were not dissimilar at 64.2+6.8 and 59.6+9.7
years respectively. Of these 6 patients, 3 had serum a subunit
concentrations greater than were predicted by MR. These 3
patients had a mean LH level of 17.6+ 11.7 IU 1- I and a
mean age of 62.6 years, compared with LH values of
38.4+14.2IUI-I and age 65.6+8.5 years in the 3 men in
whom serum oa subunit was >2.3 ngml-, but within the
value predicted by MR.
Three of the 17 men with serum a subunit values
<2.3 ngml-1 had values greater than predicted by MR.
Their mean age was 43 (37-53) years and the mean LH
value 7.3 IU 1-1 (7-8).
Following treatment mean LH concentration fell to
19.75+13.5IUVl' in the 6 men in whom serum a subunit
had been >2.3 ngml-1. Serum ca subunit remained
>2.3ngml1 in 4 of the men, but of the 3 in whom it had
been higher than predicted pre-operatively, it remained
higher than would have been predicted in 2 cases. In the 3
men in whom pre-operative serum ca subunit was within the
predicted range, no increase above the predicted range was
noted post-operatively.
Serum ac subunit in the 3 men with initial values
<2.3 ngml-l but higher than predicted by MR remained
higher than predicted in one patient.
Only one woman had a serum ci subunit value greater
than predicted.
Our data show that serum ax subunit levels are significantly
related to age and serum LH concentration. A highly signifi-
cant correlation between serum cx and LH concentrations
has been reported previously (Dosogne-Guerin et al., 1978)
but the association with age is surprising. Increased serum
ax subunit concentration may be found in primary hypo-
thyroidism and renal failure, both of which are more
common in older age groups. Measurement of serum TSH
and urea concentrations, however, showed that the relation-
ship of serum a subunit to age could not be explained on the
basis of thyroid or renal disease.
Our data suggest that the apparently high serum oc subunit
levels in some patients with tumours can, in a proportion of
cases, be explained on the basis of raised serum LH levels.
This finding may be due either to the increased secretion of
a subunit in circumstances of increased LH secretion e.g. the
pre-ovulatory LH surge in mid menstrual cycle (Rosemberg
& Bulat, 1979) or to cross-reaction of LH in the a subunit
assay (Papapetrou et al., 1985). For the purposes of our
calculations which relate serum a subunit concentration to
LH levels, the mechanism of this relationship is immaterial,
as the cross-reaction of LH and a subunit in each others
assays is consistent. The finding of variation in serum
gonadotrophin levels in patients with cancer is recognised
(Chlebowski & Heler, 1982) but the mechanism is not
known.
Multiple regression analysis allows us to distinguish
elevated serum a subunit levels which are not due to changes
in serum gonadotrophin concentration. A large study has
suggested that serum a subunit values may be related to
survival in some patients with melanoma (MacFarlane et al.,
1979). At present, however, routine use of a subunit in the
screening and monitoring of patients with cancer would not
seem to be useful in view of the problems addressed in this
study. Because of the many types of tumours which have
been associated with raised levels, however, a subunit
measurement still remains potentially valuable. Further
investigations, to determine whether serum x subunit will be
of use in the management of patients with cancer will be
facilitated by multiple regression analysis.
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